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Abstract
Background: Patient-reported outcomes (PRO) questionnaires are being increasingly used in
COPD clinical studies. The challenge facing investigators is to determine what change is significant,
ie what is the minimal clinically important difference (MCID). This study aimed to identify the MCID
for the clinical COPD questionnaire (CCQ) in terms of patient referencing, criterion referencing,
and by the standard error of measurement (SEM).
Methods: Patients were ≥40 years of age, diagnosed with COPD, had a smoking history of >10
pack-years, and were participating in a randomized, controlled clinical trial comparing intravenous
and oral prednisolone in patients admitted with an acute exacerbation of COPD. The CCQ was
completed on Days 1–7 and 42. A Global Rating of Change (GRC) assessment was taken to
establish the MCID by patient referencing. For criterion referencing, health events during a period
of 1 year after Day 42 were included in this analysis.
Results: 210 patients were recruited, 168 completed the CCQ questionnaire on Day42. The
MCID of the CCQ total score, as indicated by patient referencing in terms of the GRC, was 0.44.
The MCID of the CCQ in terms of criterion referencing for the major outcomes was 0.39, and
calculation of the SEM resulted in a value of 0.21.
Conclusion: This investigation, which is the first to determine the MCID of a PRO questionnaire
via more than one approach, indicates that the MCID of the CCQ total score is 0.4.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
major cause of morbidity and mortality in industrialized
countries. COPD affects several organs and systems, and
has a considerable impact on health status. Impaired exer-
cise tolerance, exacerbations, fatigue, muscle weakness,
depression and sleeping disorders are all features of the
disease, and although spirometry is useful for assessing
the effects of COPD on the lungs, it yields limited infor-
mation relevant to health status or symptoms. Neverthe-
less, health status has become a central feature of studies
in COPD in recent years because: (i) treatments for the
condition are largely symptomatic, and (ii) European
clinical trials are now required to incorporate a sympto-
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matic measure[1,2]. The importance of the evaluation of
health status in COPD has been demonstrated by two
studies that show correlations between health status and
other clinical outcomes. Poor scores on the St George's
Respiratory Questionnaire (SGRQ), an instrument that
measures disease specific health status, were associated
with mortality, hospital readmission and increased
healthcare resource consumption[3,4].
A number of questionnaires for the assessment of health-
related quality of life and health status which cover a
broader view of patients' well-being have been introduced
into clinical practice since the late 1980s. These include
COPD specific tools, such as the Chronic Respiratory
Questionnaire (CRQ),[5] the SGRQ (which is for both
asthma and COPD),[6] the generic instruments such as
the Medical Outcomes Study Short-Form 36 (SF-36), [7]
the Breathing Problems Questionnaire (BPQ)[8] and the
Quality of Life for Respiratory Illness Questionnaire
(QOL-RIQ)[9]. These instruments all capture valuable
data, but have levels of complexity that make them diffi-
cult to use in the routine clinic setting. This has led to the
need for a shorter and validated method to measure
health status in order to assess clinical control in clinical
trials as well as in daily clinical practice. The Clinical
COPD Questionnaire (CCQ) [see Additional file: 1] has
been developed to address this need[10].
One of the problems facing researchers using new assess-
ments of patient-reported outcomes (PRO) question-
naires is the determination of what constitutes a change
that can be considered significant [11]. This minimal clin-
ically important difference (MCID) has been defined as
'the smallest difference in a score in the domain of interest
which patients perceive as beneficial and which would
mandate in the absence of troublesome side effects and
excessive costs a change in the patient's management'[12].
The MCID can be determined by the judgment of the
patient on the basis of a Global Rating of Change (GRC)
questionnaire (patient referencing), by the clinician (cli-
nician referencing – again with a global questionnaire), or
by comparing scores on a health status instrument with a
pre-specified health criterion (criterion referencing).
These categories have been applied variously to other
instruments such as the SGRQ and CRQ[4,6,12-14]. The
aim of the present study was to identify the MCID for the
CCQ in three different ways: patient referencing, criterion
referencing, and by calculating the standard error of meas-
urement (SEM), a method that seeks correlations between
single standard error units and established MCID approx-
imations [15,16].
Patients and methods
The CCQ
The CCQ is a 10-item, self-administered questionnaire
that can be completed in less than 2 minutes. Items are
divided into three domains: symptom, functional state
and mental state; patients are required to respond to each
item on a seven-point Likert scale where 0 = asympto-
matic/no limitation and 6 = extremely symptomatic/total
limitation. The final score is the mean of all ten items, and
scores for the three domains can be calculated separately
if required. Two versions are available: a 7-day version,
which asks patients to recall their COPD status over the
past week, and a 24-hour version, which is usually used as
a diary. The CCQ has been validated and has shown
strong discriminative properties, test-retest reliability and
responsiveness[10].
Patients
From June 2001 until May 2003, data were collected from
210 patients admitted to the Isala klinieken at Zwolle, The
Netherlands with an acute exacerbation of COPD. These
patients were participating in a randomized, controlled
clinical trial designed to compare the effects of treatment
with intravenous and oral prednisolone in patients with
an acute exacerbation of COPD. Patients were at least 40
years of age and had COPD as indicated by the criteria of
the American Thoracic Society[17]. All patients had a
smoking history of more than 10 pack-years, and gave
informed and written consent before enrolment.
Patients with a history of asthma were excluded, as were
those with known hypersensitivity to prednisolone, chest
X-ray not consistent with exacerbation of COPD, arterial
PaCO2 above 9.3 kPa or acidosis (pH <7.26). Participa-
tion in another clinical trial in the four weeks preceding
randomization, presence of severe co-morbidity, and ina-
bility to follow the investigator's instructions were also
grounds for exclusion. Patients received either a 5-day
course of continuous intravenous prednisolone (60 mg/
24 hours diluted in 96 ml saline 0.9%) together with
three-times daily one placebo tablet, or a 5-day course of
three-times daily one tablet of 20 mg prednisolone with a
continuous placebo infusion (100 ml saline 0.9%/24
hours). Active and placebo medication had a similar
appearance. After 5 days all patients received oral pred-
nisolone at a dosage of 30 mg once daily, which was sub-
sequently reduced by 5 mg daily until 0 mg or a prior
maintenance dosage was reached[18].
Data collection
Patient referencing
The CCQ was completed on Days 1 to 7 and during an
outpatient visit on Day 42. A GRC assessment was also
taken on Days 2 and 3 to evaluate self-perceived changes
in disease control since the first day of admission to hos-Respiratory Research 2006, 7:62 http://respiratory-research.com/content/7/1/62
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pital. Responses were scored from +7 (a very great deal
better) to -7 (a very great deal worse); 0 indicated no
change [22]. Scores of -3, -2, +2 and +3 were considered to
represent minimal but nevertheless clinically important
changes. To establish the MCID by patient referencing, the
mean change in CCQ score from admission to Day 2 or 3
of the group with minimal change on the GRC question-
naire (-3, -2, +2 and +3) was calculated.
Criterion referencing
Health events were classified as major (hospital readmis-
sion for a pulmonary cause or death) or minor (worsening
of COPD symptoms requiring treatment with an oral cor-
ticosteroid and/or antibiotics). Major health events only
were included in the present analysis, with data pertaining
to health events in all patients who completed the CCQ
on Day 42 of the follow-up period. Data were obtained
from general practitioners and hospital records.
SEM
SEMs were calculated using the following equation:[19]
SEM = σx √1-rxx
Where (i) rxx = the reliability/intra class coefficient of the
CCQ = 0.94;[10] and (ii) σx = standard deviation of the
total CCQ on Day 42 (baseline) = 0.87.
Follow-up
Patients were followed for 12 months after completion of
the CCQ on Day 42 in order to collect data on health
events that could be matched to CCQ responses. Elec-
tronic medical dossiers at the trial centre were checked
and data were provided by general practitioners, with
information requested including dosages and lengths of
courses for oral corticosteroids and/or antibiotics, hospi-
tal admissions for COPD exacerbations, admission to
nursing homes, and death.
Statistical analysis
All analyses were performed with SPSS software version
12.0 (SPSS Inc., Chicago). A paired samples t-test was
used to test the differences between CCQ total and
domain scores on admission and on Days 2 and 3. The
Wilcoxon signed ranks test was used for the mental state
domain, since scores in this domain were skewed.
For criterion referencing, means and standard deviations
of total, functional and symptom CCQ scores were calcu-
lated. Unpaired t-tests were used to compare differences
between groups. For CCQ scores in the mental state
domain, the non-parametric Mann-Whitney U test was
used. P values less than 0.05 were considered to be statis-
tically significant.
Results
Of the 210 patients who were recruited to the clinical
study on which this analysis is based, 168 completed the
CCQ questionnaire on Day 42, 58 had global ratings of
change for Day2, 59 on Day 3 and completed the CCQ on
Day 1,2 and 3. Of the 168 patients who were followed up
in the criterion referencing population, 24% were current
smokers; the median smoking history across all these
patients was 36.5 pack-years (range: 11 to 130 pack-
years). Ages ranged from 43 to 84 years, with a median age
of 71 years. Most patients were experiencing moderate
(47.6%) or severe (33.3%) disease according to Global
Obstructive Lung Disease (GOLD) criteria[20]. The 42
patients that could not be included in the criterion refer-
encing study (14 withdrew their informed consent, 12
died before day 42, 9 were lost to follow-up, 5 had no
CCQ data, 1 had no exacerbation and 1 reported side
effects of study medication), were slightly older with a
median of 74 years, but were similar in respect to percent-
age predicted forced expiratory volume in 1 second
(FEV1), current smoking and number of pack-years.
As might be expected as a result of study intervention, the
FEV1 increased significantly in the criterion referencing
population from 37.7% to 43.2% (means, p = 0.000)
between hospital admission (Day 1) and Day 42.
Patient referencing
Tables 1 and 2 show mean CCQ changes between Days 2
and 3, respectively, grouped according to response on the
GRC scale. Twenty-one patients responded with no
change and 3 reported worsening on Day 2. On Day 3, 1
patient reported worsening whereas 10 patients reported
no change. The first category, which shows changes of +1
(no discernable or only very slight improvement),
included only very small numbers of patients on both
Days 2 and 3 and is below the threshold for clinical
change specified in the protocol. No significant change in
CCQ scores for any domain was seen for this category.
However, at the threshold for clinically relevant change
(score change of +2 or +3), some significant improve-
ments in CCQ scores became apparent: on Day 2, CCQ
changes of 0.70 for the symptom domain and 1.0 for the
mental domain fell outside the respective 95% confidence
intervals and attained statistical significance. A trend
towards significant change for the total CCQ score on Day
2 (0.40; p = 0.098) translated into statistically significant
improvement on Day 3 (0.44; p = 0.008) that was associ-
ated with a GRC improvement of +2 or +3. Statistical sig-
nificance was maintained on Day 3 for the symptom
domain, but was lost for the mental domain. Further-
more, the number of patients available for CCQ scoring in
the GRC +2 or +3 category increased from 15 on Day 2 to
20 on Day 3. These observations therefore suggest that theRespiratory Research 2006, 7:62 http://respiratory-research.com/content/7/1/62
Page 4 of 8
(page number not for citation purposes)
MCID of the CCQ total score, as indicated by patient ref-
erencing in terms of the GRC, is 0.44.
As might be expected, significant improvements in all
CCQ domains were seen in the GRC category of +4 to +5
(Table 1 and Table 2). These GRC scores represent higher
levels of patient-perceived clinical improvement that are
reflected by significant improvements in CCQ scoring
(CCQ changes ranged from 1.25 to 1.46 across domains
on Day 3), but are too great to be considered as minimally
clinically relevant. Too few patients were represented in
the maximal GRC change category (+6 to +7) on Days 2
and 3 for CCQ results to be trustworthy, but there was an
overall trend towards further increases in CCQ scores.
Criterion referencing
Differences in mean CCQ scores on Day 42 between
patients who experienced major health events (death,
rehospitalization and death and/or rehospitalization)
during the subsequent 12 months are presented in Table
3. There were no significant differences that could be
related to clinical outcomes in the mental domain of the
CCQ, but changes of interest were seen for functioning
and symptoms, and for total CCQ scores.
Day 42 total CCQ score difference was -0.8 between
patients who died and those who survived over the next
12 months (p < 0.001). CCQ differences for rehospitaliza-
tion were not as marked, however, with borderline signif-
icance being noted for the difference of -0.47 in the
function domain (p = 0.047) only. For the combined
major outcome of death and/or rehospitalization, a differ-
ence -0.39 for the total CCQ score, attained statistical sig-
nificance (Table 3). Thus, the MCID by inspection for the
CCQ in terms of criterion referencing for the major out-
comes covered in this analysis is 0.39.
Table 1: Minimal Clinically Important Difference (MCID) for the Clinical COPD Questionnaire (CCQ) by patient referencing. 
Differences between CCQ scores for Days 1 and 2 grouped according to Global Rating of Change (GRC) as scored by patients on a 
scale of -7 to 7. Note that paired-sample t-tests were used for total CCQ scores and for symptom and functional domains; Wilcoxon 
signed rank test was used for the mental domain.
CCQ score category Score difference: Day 1 minus Day 2
Mean ± SD 95% confidence interval p value
GRC +1 (n = 3)
Total 0.30 ± 0.30 -0.45, 1.05 0.225
Symptoms -0.25 ± 1.64 -4.32, 3.82 0.816
Function 1.17 ± 0.80 -0.83, 3.16 0.128
Mental -0.5§ 0.157
GRC +2 to +3 (n = 15)
Total 0.40 ± 0.90 -0.09, 0.91 0.098
Symptoms 0.70 ± 1.09 0.98, 1.30 0.026*
Function 0.17 ± 1.37 -0.93, 0.59 0.645
Mental 1.0§ 0.007*
GRC +4 to +5 (n = 14)
Total 1.31 ± 1.09 0.69, 1.94 0.001*
Symptoms 1.13 ± 1.52 0.25, 2.0 0.016*
Function 1.48 ± 1.25 0.76, 2.20 0.001*
Mental 0.5§ 0.018*
GRC +6 to +7 (n = 2)
Total 1.95 ± 0.07 1.31, 2.59 0.016*
Symptoms 2.75 ± 1.77 -13.13, 18.63 0.272
Function 1.50 ± 1.06 -8.03, 11.03 0.295
Mental 1.25§ 0.317
* Statistically significant (2-tailed): p < 0.05. § Difference in median scores
COPD = chronic obstructive pulmonary disease; SD = standard deviation.Respiratory Research 2006, 7:62 http://respiratory-research.com/content/7/1/62
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SEM
Calculation of the SEM using the described method
resulted in a SEM of 0.21.
Discussion
The methods used in the present analysis to determine the
MCID for the CCQ yielded similar findings with patient
and criterion referencing (0.44 and 0.39 units respec-
tively). However the SEM was much lower (0.21). In light
of these observations, we suggest that the MCID of the
CCQ instrument is approximately 0.4 points. Thus, a
change in score of 0.4 or more from baseline indicates the
smallest change indicated by the CCQ in health status that
can be considered to be clinically significant.
The first method used, patient referencing, was based on
CCQ changes linked to a prespecified global rating of
change of +2 to +3 points over the first 3 days of treat-
ment. In both this group and that with the next level of
improvement (GRC change of +4 to +5), sufficient num-
bers of patients were available for clear patterns of change
in the CCQ to be evident. The very small numbers of
patients and consequent inconclusive results in the
groups showing least (GRC change +1) and most (GRC
change +6 to +7) clinical improvement was of little
importance in the setting of the present analysis, as the
change in health status of these patients was either too
small or too large to be of interest.
Patient referencing has been used extensively by other
investigators calculating MCIDs of PRO instruments, and
our results are in broad agreement with these other find-
ings. Furthermore, although this approach has not been
formally validated, there is ample evidence that the global
assessments used correlate well with PRO questionnaires.
Jaeschke and colleagues[12] performed an analysis in 55
patients with COPD who had participated in two clinical
Table 2: Minimal Clinically Important Difference (MCID) for the Clinical COPD Questionnaire (CCQ) by patient referencing. 
Differences between CCQ scores for Days 1 and 3 grouped according to Global Rating of Change (GRC) as scored by patients on a 
scale of -7 to 7. Note that paired-sample t-tests were used for total CCQ scores and for symptom and functional domains; Wilcoxon 
signed rank test was used for the mental domain.
CCQ score category Score difference: Day 1 minus Day 3
Mean ± SD 95% confidence interval p value
GRC +1 (n = 4)
Total 0.05 ± 0.49 -0.73, 0.83 0.852
Symptoms 0 ± 1.02 -1.62, 1.62 1.0
Function 0 ± 1.02 -1.62, 1.62 1.0
Mental 0.25§ 0.414
GRC +2 to +3 (n = 20)
Total 0.44 ± 0.66 0.13, 0.75 0.008*
Symptoms 0.74 ± 0.93 0.30, 1.17 0.002*
Function 0.26 ± 0.995 -0.20, 0.72 0.253
Mental 0.25§ 0.398
GRC +4 to +5 (n = 20)
Total 1.36 ± 1.07 0.86, 1.86 <0.001*
Symptoms 1.46 ± 0.99 1.0, 1.92 <0.001*
Function 1.31 ± 1.65 0.54, 2.08 0.002*
Mental 1.75§ 0.023*
GRC +6 to +7 (n = 4)
Total 1.95 ± 0.87 0.56, 3.34 0.021*
Symptoms 2.37 ± 1.13 0.58, 4.17 0.024*
Function 2.31 ± 0.90 0.88, 3.74 0.014*
Mental -0.25§ 0.655
* Statistically significant (2-tailed): p < 0.05. § Difference in median scores
COPD = chronic obstructive pulmonary disease; SD = standard deviation.Respiratory Research 2006, 7:62 http://respiratory-research.com/content/7/1/62
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trials and in 20 patients with heart failure. Changes in
CRQ[5] and Chronic Heart Failure Questionnaire
(CHQ)[21] scores were compared with retrospective glo-
bal estimates of change by the patients themselves on a
15-point transition scale similar to our GRC (seven cate-
gories of improvement, seven of deterioration and one of
no change). The authors set the threshold for clinical sig-
nificance on this scale as 'almost the same, hardly any bet-
ter (or worse)', 'a little better (or worse)' or 'somewhat
better (or worse)', the last two of which approximate to
the change of 2 to 3 on the scale used here. Although there
was considerable variation between patients in MCID esti-
mates, mean changes corresponding to the predefined
threshold were 0.43 for dyspnea, 0.64 for fatigue, and
0.49 for emotional function. Jaeschke and colleagues[12]
concluded that the mean change in score per question
that corresponded to the MCID was consistently around
0.5.
Juniper et al[22] adopted a similar approach to determine
an MCID for the Asthma Quality of Life Questionnaire
(AQLQ), except that their threshold for minimally signif-
icant change was more similar to ours than that adopted
by Jaeschke et al:[12] AQLQ scores that corresponded to
'a little better (or worse)' and 'somewhat better (or worse)'
were used. In this analysis, each of 39 patients attending
an asthma clinic was followed for 8 weeks. For overall
asthma-specific quality of life and for all individual
domains (activities, emotions and symptoms), the MCID
per item was close to 0.5 (0.42 to 0.58). Differences of
approximately 1.0 corresponded to moderate change, and
large changes were accompanied by score changes of
around 1.5.
It is worth noting at this point that more noticeable global
changes as shown by the GRC were accompanied in our
analysis by larger CCQ changes. By Day 3, a GRC of +4 to
+5 was associated with mean increases in CCQ scores of
1.25 to 1.46 for the separate domains, and an increase in
total mean score of 1.36. These changes were consistent
across domains and were all statistically significant.
Further data in patients with asthma are available from a
1-year study in which 719 adults received nedocromil
Table 3: Minimal Clinically Important Difference (MCID) for the Clinical COPD Questionnaire (CCQ) by criterion referencing. 
Differences between baseline (Day 42) CCQ scores are grouped according to major health events during 12-month follow-up. 
Unpaired-sample t-tests were used for total CCQ scores and for symptom and functional domains, with equal variances assumed; the 
Mann-Whitney U test was used for the mental domain.
CCQ score category Score difference
Mean 95% confidence interval p value
Death (n = 25) or survival (n = 
143)
Total -0.80 -1.23, -0.37 <0.001*
Symptoms -0.62 -1.13, -0.12 0.015*
Function -1.32 -1.90, -0.74 <0.001*
Mental 0.5§ 0.211
Rehospitalization (n = 56) or 
not (n = 112)
Total -0.18 -0.52, 0.16 0.290
Symptoms -0.07 -0.46–0.31 0.706
Function -0.47 -0.93, -0.007 0.047*
Mental 0§ 0.505
Death/rehospitalization (n = 
70) versus survival/no 
rehospitalization (n = 98)
Total -0.39 -0.71, -0.07 0.017*
Symptoms -0.27 -0.63, 0.10 0.153
Function -0.77 -1.19, -0.34 0.001*
Mental 0§ 0.987
* Statistically significant (2-tailed): p < 0.05. § Difference in median scores
COPD = chronic obstructive pulmonary disease.Respiratory Research 2006, 7:62 http://respiratory-research.com/content/7/1/62
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sodium or placebo and were assessed with the SGRQ[23].
Differences in scores from baseline to 12 months were
compared with patients' own retrospective estimates of
treatment efficacy, and there was a rank order correlation
between change in health-related quality of life and over-
all judgement of treatment efficacy. Patients who judged
treatment to be 'slightly effective' showed a mean 4.0-unit
change on the SGRQ[24]. In another study,[25] 87
patients who judged treatment with salmeterol to be 'sat-
isfactory' showed a mean change in SGRQ of 2.0 points
over 16 weeks. This term, however, was deemed ambigu-
ous[13]. The lowest response category compatible with
efficacy, 'effective', corresponded with a mean SGRQ
change of 4.3 units in 109 patients.
Although it is not possible to compare these authors'
results with those reported here because of the different
PRO questionnaires and health status scales examined, it
is clear that all these investigators were readily able to
identify MCIDs by patient referencing methods. Further-
more, patterns of findings across the different studies are
remarkably consistent, and show not only the smallest
discernible changes, but also consistent increases in
health status scores in parallel with patients' own percep-
tions of greater clinical improvement.
The criterion referencing approach compares health status
scores to a specified health-related variable on the under-
standing that PRO questionnaire scores should be worse
in patients who have major health events than in those
who do not. Upon examination of CCQ scores catego-
rized according to the major health outcomes of death,
rehospitalization, and death and/or rehospitalization, we
found the smallest statistically significant score change
associated with one of these outcomes to be 0.39. Score
changes that exceeded this value were found to be consist-
ently significant, while lower scores failed to attain signif-
icance.
It should also be noted that MCIDs determined by this
method might be expected to have predictive value, as the
CCQ score differences were noted at baseline point of
study Day 42 and corresponded to subsequent health out-
comes reported 1 year later. Thus, it can be concluded that
when a difference in CCQ score between two patients
with COPD exceeds 0.39 points, the patient with the
higher score has an increased risk of dying and/or being
readmitted to hospital during the course of the following
year. Overall, the smallest CCQ differences were found to
be those between patients who were readmitted to hospi-
tal and those who were not, whereas the score differences
between patients who died and those who survived were
the largest. This predictive value concurs with results of
other studies, such as Domingo-Salvany et al.[3] who
reported a link between reduced duration of survival for
male patients with COPD and poor health-related quality
of life. In addition, Osman and colleagues[4] found poor
SGRQ scores to be associated with increased risk of hospi-
tal readmission for COPD.
The similarity between MCIDs determined by patient and
criterion referencing for the CCQ as noted in the present
analysis has been apparent in research into other health-
related quality of life scales. SGRQ scores at baseline dif-
fered by 4.8 units between patients who were admitted to
hospital or died and those who experienced neither of
these outcomes in the year following discharge from hos-
pital for an acute exacerbation of asthma in a study in 238
individuals[4]. Similarly, in a study in patients with
COPD, SGRQ scores were related to Medical Research
Council dyspnea gradings[26]. In 32 patients with a grad-
ing of 5 (housebound), SGRQ scores were 3.9 units worse
than in patients who had major impairment but who were
not housebound (grade 4).
The SEM has not been used in many studies for establish-
ing the MCID of PRO questionnaires. For the CRQ, one-
SEM appears to be closely related to the MCID of the
CRQ[15]. In this study the SEM was found to be 0.21,
which is lower than the other two methods used for estab-
lishing the MCID of the CCQ. This might be because of
the high reliability/intra-class coefficient. Some researches
take a more conservative approach to the assessment of
the MCID using the SEM. They use the 1.96 SEM, which
represents a 95% confidence interval[19]. Using this con-
servative measure, the MCID is 0.41, a similar result to
that produced by the two other methods.
Thus, the present investigation, which is the first to deter-
mine the MCID of a PRO questionnaire via more than one
approach, indicates that the MCID of the CCQ total score
is 0.4. Our findings also demonstrate the predictive value
of such differences in terms of longer term major health
outcomes in patients with COPD.
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